What is the current valuation of the Brucellosis Market as of 2024?

The Brucellosis Market was valued at 657.55 USD Million in 2024. Read More

What is the projected market valuation for the Brucellosis Market in 2035?

The projected valuation for the Brucellosis Market in 2035 is 1380.04 USD Million. Read More

What is the expected CAGR for the Brucellosis Market during the forecast period 2025 - 2035?

The expected CAGR for the Brucellosis Market during the forecast period 2025 - 2035 is 6.93%. Read More

Which companies are considered key players in the Brucellosis Market?

Key players in the Brucellosis Market include Zoetis, Merck Animal Health, Boehringer Ingelheim, and others. Read More

What are the main application segments of the Brucellosis Market?

The main application segments include Diagnosis, Vaccination, Research, and Surveillance. Read More

How much was the Vaccination segment valued at in 2024?

The Vaccination segment was valued at 200.0 USD Million in 2024. Read More

What is the projected value of the Veterinary end-use segment by 2035?

The Veterinary end-use segment is projected to reach 400.0 USD Million by 2035. Read More

Which pathogen type segment had the highest valuation in 2024?

The Brucella melitensis pathogen type segment had the highest valuation at 200.0 USD Million in 2024. Read More

What are the different test types used in the Brucellosis Market?

Test types include Serological Tests, Molecular Tests, Culture Tests, and Skin Tests. Read More

What was the valuation of the Skin Tests segment in 2024?

The Skin Tests segment was valued at 207.55 USD Million in 2024. Read More

Brucellosis Market

ID: MRFR/LS/3722-HCR

90 Pages

Rahul Gotadki

Last Updated: May 15, 2026

Brucellosis Market research report– by species (Brucella suis, B. abortus, B. melitensis), Diagnosis (serological tests, molecular techniques, bone marrow biopsy, CT, MRI), Treatment (vaccine, antibiotics), End user– Forecast till 2035.

Brucellosis Market

Market Size

Forecast Period2025 - 2035

CAGR (2025 - 2035)6.93%

2024 Market Size$ 657.55 Million

2025 Market Size$ 710.65 Million

2035 Market Size$ 1,380.04 Million

Key Players

Zoetis

Merck Animal Health

Boehringer Ingelheim

Ceva Santé Animale

Vetoquinol

Heska Corporation

Trends

Rising Awareness of Zoonotic Diseases
Advancements in Diagnostic Technologies
Research and Development Initiatives

Opportunities

Rising Incidence of Brucellosis
Government Initiatives and Funding
Growing Awareness of Zoonotic Diseases

Summary Table of Contents Segmentation Methodology Download PDF

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Healthcare, BY Application (USD Million)
  1. 4.1.1 Diagnosis
  2. 4.1.2 Vaccination
  3. 4.1.3 Research
  4. 4.1.4 Surveillance
2. 4.2 Healthcare, BY End Use (USD Million)
  1. 4.2.1 Healthcare
  2. 4.2.2 Veterinary
  3. 4.2.3 Pharmaceuticals
  4. 4.2.4 Research Institutions
3. 4.3 Healthcare, BY Pathogen Type (USD Million)
  1. 4.3.1 Brucella abortus
  2. 4.3.2 Brucella melitensis
  3. 4.3.3 Brucella suis
  4. 4.3.4 Brucella canis
4. 4.4 Healthcare, BY Test Type (USD Million)
  1. 4.4.1 Serological Tests
  2. 4.4.2 Molecular Tests
  3. 4.4.3 Culture Tests
  4. 4.4.4 Skin Tests
5. 4.5 Healthcare, BY Region (USD Million)
  1. 4.5.1 North America
    1. 4.5.1.1 US
    2. 4.5.1.2 Canada
  2. 4.5.2 Europe
    1. 4.5.2.1 Germany
    2. 4.5.2.2 UK
    3. 4.5.2.3 France
    4. 4.5.2.4 Russia
    5. 4.5.2.5 Italy
    6. 4.5.2.6 Spain
    7. 4.5.2.7 Rest of Europe
  3. 4.5.3 APAC
    1. 4.5.3.1 China
    2. 4.5.3.2 India
    3. 4.5.3.3 Japan
    4. 4.5.3.4 South Korea
    5. 4.5.3.5 Malaysia
    6. 4.5.3.6 Thailand
    7. 4.5.3.7 Indonesia
    8. 4.5.3.8 Rest of APAC
  4. 4.5.4 South America
    1. 4.5.4.1 Brazil
    2. 4.5.4.2 Mexico
    3. 4.5.4.3 Argentina
    4. 4.5.4.4 Rest of South America
  5. 4.5.5 MEA
    1. 4.5.5.1 GCC Countries
    2. 4.5.5.2 South Africa
    3. 4.5.5.3 Rest of MEA
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Healthcare
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Zoetis (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Merck Animal Health (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Boehringer Ingelheim (DE)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Ceva Santé Animale (FR)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Vetoquinol (FR)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Heska Corporation (US)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Elanco Animal Health (US)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Virbac (FR)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 NORTH AMERICA MARKET ANALYSIS
3. 6.3 US MARKET ANALYSIS BY APPLICATION
4. 6.4 US MARKET ANALYSIS BY END USE
5. 6.5 US MARKET ANALYSIS BY PATHOGEN TYPE
6. 6.6 US MARKET ANALYSIS BY TEST TYPE
7. 6.7 CANADA MARKET ANALYSIS BY APPLICATION
8. 6.8 CANADA MARKET ANALYSIS BY END USE
9. 6.9 CANADA MARKET ANALYSIS BY PATHOGEN TYPE
10. 6.10 CANADA MARKET ANALYSIS BY TEST TYPE
11. 6.11 EUROPE MARKET ANALYSIS
12. 6.12 GERMANY MARKET ANALYSIS BY APPLICATION
13. 6.13 GERMANY MARKET ANALYSIS BY END USE
14. 6.14 GERMANY MARKET ANALYSIS BY PATHOGEN TYPE
15. 6.15 GERMANY MARKET ANALYSIS BY TEST TYPE
16. 6.16 UK MARKET ANALYSIS BY APPLICATION
17. 6.17 UK MARKET ANALYSIS BY END USE
18. 6.18 UK MARKET ANALYSIS BY PATHOGEN TYPE
19. 6.19 UK MARKET ANALYSIS BY TEST TYPE
20. 6.20 FRANCE MARKET ANALYSIS BY APPLICATION
21. 6.21 FRANCE MARKET ANALYSIS BY END USE
22. 6.22 FRANCE MARKET ANALYSIS BY PATHOGEN TYPE
23. 6.23 FRANCE MARKET ANALYSIS BY TEST TYPE
24. 6.24 RUSSIA MARKET ANALYSIS BY APPLICATION
25. 6.25 RUSSIA MARKET ANALYSIS BY END USE
26. 6.26 RUSSIA MARKET ANALYSIS BY PATHOGEN TYPE
27. 6.27 RUSSIA MARKET ANALYSIS BY TEST TYPE
28. 6.28 ITALY MARKET ANALYSIS BY APPLICATION
29. 6.29 ITALY MARKET ANALYSIS BY END USE
30. 6.30 ITALY MARKET ANALYSIS BY PATHOGEN TYPE
31. 6.31 ITALY MARKET ANALYSIS BY TEST TYPE
32. 6.32 SPAIN MARKET ANALYSIS BY APPLICATION
33. 6.33 SPAIN MARKET ANALYSIS BY END USE
34. 6.34 SPAIN MARKET ANALYSIS BY PATHOGEN TYPE
35. 6.35 SPAIN MARKET ANALYSIS BY TEST TYPE
36. 6.36 REST OF EUROPE MARKET ANALYSIS BY APPLICATION
37. 6.37 REST OF EUROPE MARKET ANALYSIS BY END USE
38. 6.38 REST OF EUROPE MARKET ANALYSIS BY PATHOGEN TYPE
39. 6.39 REST OF EUROPE MARKET ANALYSIS BY TEST TYPE
40. 6.40 APAC MARKET ANALYSIS
41. 6.41 CHINA MARKET ANALYSIS BY APPLICATION
42. 6.42 CHINA MARKET ANALYSIS BY END USE
43. 6.43 CHINA MARKET ANALYSIS BY PATHOGEN TYPE
44. 6.44 CHINA MARKET ANALYSIS BY TEST TYPE
45. 6.45 INDIA MARKET ANALYSIS BY APPLICATION
46. 6.46 INDIA MARKET ANALYSIS BY END USE
47. 6.47 INDIA MARKET ANALYSIS BY PATHOGEN TYPE
48. 6.48 INDIA MARKET ANALYSIS BY TEST TYPE
49. 6.49 JAPAN MARKET ANALYSIS BY APPLICATION
50. 6.50 JAPAN MARKET ANALYSIS BY END USE
51. 6.51 JAPAN MARKET ANALYSIS BY PATHOGEN TYPE
52. 6.52 JAPAN MARKET ANALYSIS BY TEST TYPE
53. 6.53 SOUTH KOREA MARKET ANALYSIS BY APPLICATION
54. 6.54 SOUTH KOREA MARKET ANALYSIS BY END USE
55. 6.55 SOUTH KOREA MARKET ANALYSIS BY PATHOGEN TYPE
56. 6.56 SOUTH KOREA MARKET ANALYSIS BY TEST TYPE
57. 6.57 MALAYSIA MARKET ANALYSIS BY APPLICATION
58. 6.58 MALAYSIA MARKET ANALYSIS BY END USE
59. 6.59 MALAYSIA MARKET ANALYSIS BY PATHOGEN TYPE
60. 6.60 MALAYSIA MARKET ANALYSIS BY TEST TYPE
61. 6.61 THAILAND MARKET ANALYSIS BY APPLICATION
62. 6.62 THAILAND MARKET ANALYSIS BY END USE
63. 6.63 THAILAND MARKET ANALYSIS BY PATHOGEN TYPE
64. 6.64 THAILAND MARKET ANALYSIS BY TEST TYPE
65. 6.65 INDONESIA MARKET ANALYSIS BY APPLICATION
66. 6.66 INDONESIA MARKET ANALYSIS BY END USE
67. 6.67 INDONESIA MARKET ANALYSIS BY PATHOGEN TYPE
68. 6.68 INDONESIA MARKET ANALYSIS BY TEST TYPE
69. 6.69 REST OF APAC MARKET ANALYSIS BY APPLICATION
70. 6.70 REST OF APAC MARKET ANALYSIS BY END USE
71. 6.71 REST OF APAC MARKET ANALYSIS BY PATHOGEN TYPE
72. 6.72 REST OF APAC MARKET ANALYSIS BY TEST TYPE
73. 6.73 SOUTH AMERICA MARKET ANALYSIS
74. 6.74 BRAZIL MARKET ANALYSIS BY APPLICATION
75. 6.75 BRAZIL MARKET ANALYSIS BY END USE
76. 6.76 BRAZIL MARKET ANALYSIS BY PATHOGEN TYPE
77. 6.77 BRAZIL MARKET ANALYSIS BY TEST TYPE
78. 6.78 MEXICO MARKET ANALYSIS BY APPLICATION
79. 6.79 MEXICO MARKET ANALYSIS BY END USE
80. 6.80 MEXICO MARKET ANALYSIS BY PATHOGEN TYPE
81. 6.81 MEXICO MARKET ANALYSIS BY TEST TYPE
82. 6.82 ARGENTINA MARKET ANALYSIS BY APPLICATION
83. 6.83 ARGENTINA MARKET ANALYSIS BY END USE
84. 6.84 ARGENTINA MARKET ANALYSIS BY PATHOGEN TYPE
85. 6.85 ARGENTINA MARKET ANALYSIS BY TEST TYPE
86. 6.86 REST OF SOUTH AMERICA MARKET ANALYSIS BY APPLICATION
87. 6.87 REST OF SOUTH AMERICA MARKET ANALYSIS BY END USE
88. 6.88 REST OF SOUTH AMERICA MARKET ANALYSIS BY PATHOGEN TYPE
89. 6.89 REST OF SOUTH AMERICA MARKET ANALYSIS BY TEST TYPE
90. 6.90 MEA MARKET ANALYSIS
91. 6.91 GCC COUNTRIES MARKET ANALYSIS BY APPLICATION
92. 6.92 GCC COUNTRIES MARKET ANALYSIS BY END USE
93. 6.93 GCC COUNTRIES MARKET ANALYSIS BY PATHOGEN TYPE
94. 6.94 GCC COUNTRIES MARKET ANALYSIS BY TEST TYPE
95. 6.95 SOUTH AFRICA MARKET ANALYSIS BY APPLICATION
96. 6.96 SOUTH AFRICA MARKET ANALYSIS BY END USE
97. 6.97 SOUTH AFRICA MARKET ANALYSIS BY PATHOGEN TYPE
98. 6.98 SOUTH AFRICA MARKET ANALYSIS BY TEST TYPE
99. 6.99 REST OF MEA MARKET ANALYSIS BY APPLICATION
100. 6.100 REST OF MEA MARKET ANALYSIS BY END USE
101. 6.101 REST OF MEA MARKET ANALYSIS BY PATHOGEN TYPE
102. 6.102 REST OF MEA MARKET ANALYSIS BY TEST TYPE
103. 6.103 KEY BUYING CRITERIA OF HEALTHCARE
104. 6.104 RESEARCH PROCESS OF MRFR
105. 6.105 DRO ANALYSIS OF HEALTHCARE
106. 6.106 DRIVERS IMPACT ANALYSIS: HEALTHCARE
107. 6.107 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
108. 6.108 SUPPLY / VALUE CHAIN: HEALTHCARE
109. 6.109 HEALTHCARE, BY APPLICATION, 2024 (% SHARE)
110. 6.110 HEALTHCARE, BY APPLICATION, 2024 TO 2035 (USD Million)
111. 6.111 HEALTHCARE, BY END USE, 2024 (% SHARE)
112. 6.112 HEALTHCARE, BY END USE, 2024 TO 2035 (USD Million)
113. 6.113 HEALTHCARE, BY PATHOGEN TYPE, 2024 (% SHARE)
114. 6.114 HEALTHCARE, BY PATHOGEN TYPE, 2024 TO 2035 (USD Million)
115. 6.115 HEALTHCARE, BY TEST TYPE, 2024 (% SHARE)
116. 6.116 HEALTHCARE, BY TEST TYPE, 2024 TO 2035 (USD Million)
117. 6.117 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 North America MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY APPLICATION, 2025-2035 (USD Million)
  2. 7.2.2 BY END USE, 2025-2035 (USD Million)
  3. 7.2.3 BY PATHOGEN TYPE, 2025-2035 (USD Million)
  4. 7.2.4 BY TEST TYPE, 2025-2035 (USD Million)
2. 7.3 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.3.1 BY APPLICATION, 2025-2035 (USD Million)
  2. 7.3.2 BY END USE, 2025-2035 (USD Million)
  3. 7.3.3 BY PATHOGEN TYPE, 2025-2035 (USD Million)
  4. 7.3.4 BY TEST TYPE, 2025-2035 (USD Million)
3. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST
  1. 7.4.1 BY APPLICATION, 2025-2035 (USD Million)
  2. 7.4.2 BY END USE, 2025-2035 (USD Million)
  3. 7.4.3 BY PATHOGEN TYPE, 2025-2035 (USD Million)
  4. 7.4.4 BY TEST TYPE, 2025-2035 (USD Million)
4. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST
  1. 7.5.1 BY APPLICATION, 2025-2035 (USD Million)
  2. 7.5.2 BY END USE, 2025-2035 (USD Million)
  3. 7.5.3 BY PATHOGEN TYPE, 2025-2035 (USD Million)
  4. 7.5.4 BY TEST TYPE, 2025-2035 (USD Million)
5. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST
  1. 7.6.1 BY APPLICATION, 2025-2035 (USD Million)
  2. 7.6.2 BY END USE, 2025-2035 (USD Million)
  3. 7.6.3 BY PATHOGEN TYPE, 2025-2035 (USD Million)
  4. 7.6.4 BY TEST TYPE, 2025-2035 (USD Million)
6. 7.7 UK MARKET SIZE ESTIMATES; FORECAST
  1. 7.7.1 BY APPLICATION, 2025-2035 (USD Million)
  2. 7.7.2 BY END USE, 2025-2035 (USD Million)
  3. 7.7.3 BY PATHOGEN TYPE, 2025-2035 (USD Million)
  4. 7.7.4 BY TEST TYPE, 2025-2035 (USD Million)
7. 7.8 France MARKET SIZE ESTIMATES; FORECAST
  1. 7.8.1 BY APPLICATION, 2025-2035 (USD Million)
  2. 7.8.2 BY END USE, 2025-2035 (USD Million)
  3. 7.8.3 BY PATHOGEN TYPE, 2025-2035 (USD Million)
  4. 7.8.4 BY TEST TYPE, 2025-2035 (USD Million)
8. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST
  1. 7.9.1 BY APPLICATION, 2025-2035 (USD Million)
  2. 7.9.2 BY END USE, 2025-2035 (USD Million)
  3. 7.9.3 BY PATHOGEN TYPE, 2025-2035 (USD Million)
  4. 7.9.4 BY TEST TYPE, 2025-2035 (USD Million)
9. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST
  1. 7.10.1 BY APPLICATION, 2025-2035 (USD Million)
  2. 7.10.2 BY END USE, 2025-2035 (USD Million)
  3. 7.10.3 BY PATHOGEN TYPE, 2025-2035 (USD Million)
  4. 7.10.4 BY TEST TYPE, 2025-2035 (USD Million)
10. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST
  1. 7.11.1 BY APPLICATION, 2025-2035 (USD Million)
  2. 7.11.2 BY END USE, 2025-2035 (USD Million)
  3. 7.11.3 BY PATHOGEN TYPE, 2025-2035 (USD Million)
  4. 7.11.4 BY TEST TYPE, 2025-2035 (USD Million)
11. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
  1. 7.12.1 BY APPLICATION, 2025-2035 (USD Million)
  2. 7.12.2 BY END USE, 2025-2035 (USD Million)
  3. 7.12.3 BY PATHOGEN TYPE, 2025-2035 (USD Million)
  4. 7.12.4 BY TEST TYPE, 2025-2035 (USD Million)
12. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST
  1. 7.13.1 BY APPLICATION, 2025-2035 (USD Million)
  2. 7.13.2 BY END USE, 2025-2035 (USD Million)
  3. 7.13.3 BY PATHOGEN TYPE, 2025-2035 (USD Million)
  4. 7.13.4 BY TEST TYPE, 2025-2035 (USD Million)
13. 7.14 China MARKET SIZE ESTIMATES; FORECAST
  1. 7.14.1 BY APPLICATION, 2025-2035 (USD Million)
  2. 7.14.2 BY END USE, 2025-2035 (USD Million)
  3. 7.14.3 BY PATHOGEN TYPE, 2025-2035 (USD Million)
  4. 7.14.4 BY TEST TYPE, 2025-2035 (USD Million)
14. 7.15 India MARKET SIZE ESTIMATES; FORECAST
  1. 7.15.1 BY APPLICATION, 2025-2035 (USD Million)
  2. 7.15.2 BY END USE, 2025-2035 (USD Million)
  3. 7.15.3 BY PATHOGEN TYPE, 2025-2035 (USD Million)
  4. 7.15.4 BY TEST TYPE, 2025-2035 (USD Million)
15. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST
  1. 7.16.1 BY APPLICATION, 2025-2035 (USD Million)
  2. 7.16.2 BY END USE, 2025-2035 (USD Million)
  3. 7.16.3 BY PATHOGEN TYPE, 2025-2035 (USD Million)
  4. 7.16.4 BY TEST TYPE, 2025-2035 (USD Million)
16. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
  1. 7.17.1 BY APPLICATION, 2025-2035 (USD Million)
  2. 7.17.2 BY END USE, 2025-2035 (USD Million)
  3. 7.17.3 BY PATHOGEN TYPE, 2025-2035 (USD Million)
  4. 7.17.4 BY TEST TYPE, 2025-2035 (USD Million)
17. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
  1. 7.18.1 BY APPLICATION, 2025-2035 (USD Million)
  2. 7.18.2 BY END USE, 2025-2035 (USD Million)
  3. 7.18.3 BY PATHOGEN TYPE, 2025-2035 (USD Million)
  4. 7.18.4 BY TEST TYPE, 2025-2035 (USD Million)
18. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
  1. 7.19.1 BY APPLICATION, 2025-2035 (USD Million)
  2. 7.19.2 BY END USE, 2025-2035 (USD Million)
  3. 7.19.3 BY PATHOGEN TYPE, 2025-2035 (USD Million)
  4. 7.19.4 BY TEST TYPE, 2025-2035 (USD Million)
19. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
  1. 7.20.1 BY APPLICATION, 2025-2035 (USD Million)
  2. 7.20.2 BY END USE, 2025-2035 (USD Million)
  3. 7.20.3 BY PATHOGEN TYPE, 2025-2035 (USD Million)
  4. 7.20.4 BY TEST TYPE, 2025-2035 (USD Million)
20. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
  1. 7.21.1 BY APPLICATION, 2025-2035 (USD Million)
  2. 7.21.2 BY END USE, 2025-2035 (USD Million)
  3. 7.21.3 BY PATHOGEN TYPE, 2025-2035 (USD Million)
  4. 7.21.4 BY TEST TYPE, 2025-2035 (USD Million)
21. 7.22 South America MARKET SIZE ESTIMATES; FORECAST
  1. 7.22.1 BY APPLICATION, 2025-2035 (USD Million)
  2. 7.22.2 BY END USE, 2025-2035 (USD Million)
  3. 7.22.3 BY PATHOGEN TYPE, 2025-2035 (USD Million)
  4. 7.22.4 BY TEST TYPE, 2025-2035 (USD Million)
22. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
  1. 7.23.1 BY APPLICATION, 2025-2035 (USD Million)
  2. 7.23.2 BY END USE, 2025-2035 (USD Million)
  3. 7.23.3 BY PATHOGEN TYPE, 2025-2035 (USD Million)
  4. 7.23.4 BY TEST TYPE, 2025-2035 (USD Million)
23. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
  1. 7.24.1 BY APPLICATION, 2025-2035 (USD Million)
  2. 7.24.2 BY END USE, 2025-2035 (USD Million)
  3. 7.24.3 BY PATHOGEN TYPE, 2025-2035 (USD Million)
  4. 7.24.4 BY TEST TYPE, 2025-2035 (USD Million)
24. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
  1. 7.25.1 BY APPLICATION, 2025-2035 (USD Million)
  2. 7.25.2 BY END USE, 2025-2035 (USD Million)
  3. 7.25.3 BY PATHOGEN TYPE, 2025-2035 (USD Million)
  4. 7.25.4 BY TEST TYPE, 2025-2035 (USD Million)
25. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
  1. 7.26.1 BY APPLICATION, 2025-2035 (USD Million)
  2. 7.26.2 BY END USE, 2025-2035 (USD Million)
  3. 7.26.3 BY PATHOGEN TYPE, 2025-2035 (USD Million)
  4. 7.26.4 BY TEST TYPE, 2025-2035 (USD Million)
26. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST
  1. 7.27.1 BY APPLICATION, 2025-2035 (USD Million)
  2. 7.27.2 BY END USE, 2025-2035 (USD Million)
  3. 7.27.3 BY PATHOGEN TYPE, 2025-2035 (USD Million)
  4. 7.27.4 BY TEST TYPE, 2025-2035 (USD Million)
27. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
  1. 7.28.1 BY APPLICATION, 2025-2035 (USD Million)
  2. 7.28.2 BY END USE, 2025-2035 (USD Million)
  3. 7.28.3 BY PATHOGEN TYPE, 2025-2035 (USD Million)
  4. 7.28.4 BY TEST TYPE, 2025-2035 (USD Million)
28. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
  1. 7.29.1 BY APPLICATION, 2025-2035 (USD Million)
  2. 7.29.2 BY END USE, 2025-2035 (USD Million)
  3. 7.29.3 BY PATHOGEN TYPE, 2025-2035 (USD Million)
  4. 7.29.4 BY TEST TYPE, 2025-2035 (USD Million)
29. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
  1. 7.30.1 BY APPLICATION, 2025-2035 (USD Million)
  2. 7.30.2 BY END USE, 2025-2035 (USD Million)
  3. 7.30.3 BY PATHOGEN TYPE, 2025-2035 (USD Million)
  4. 7.30.4 BY TEST TYPE, 2025-2035 (USD Million)
30. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.31.1
1. 7.32 ACQUISITION/PARTNERSHIP
7.32.1

Certified Researchers

Customize Report

Brucellosis Market Segmentation

Brucellosis Market By Application (USD Million, 2025-2035)

Diagnosis
Vaccination
Research
Surveillance

Brucellosis Market By End Use (USD Million, 2025-2035)

Brucellosis Market
Veterinary
Brucellosis Markets
Research Institutions

Brucellosis Market By Pathogen Type (USD Million, 2025-2035)

Brucella abortus
Brucella melitensis
Brucella suis
Brucella canis

Brucellosis Market By Test Type (USD Million, 2025-2035)

Serological Tests
Molecular Tests
Culture Tests
Skin Tests

Certified Researchers

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”